TAKEDA PHARMACEUTICAL CO LTD will cut 4,500 jobs by the end of fiscal 2026 to centralize corporate functions and reduce costs. The restructuring follows debt and complexity from its $62 billion acquisition of Shire in 2019. Investors are monitoring the drugmaker's ability to generate 200 billion yen ($1.27 billion) in annual savings by fiscal 2028.

Restructuring Costs and Savings Targets